Circulating tumor DNA as a marker for treatment response in metastatic melanoma patients using next-generation sequencing: a prospective feasibility study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers, 13, 12, S. 3101-
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2021
- Ereignis
-
Veröffentlichung
- (wer)
-
MDPI AG
- (wann)
-
2021
- Urheber
-
Berger, Marina
Thueringer, Andrea
Franz, Doritt
Dandachi, Nadia
Talakić, Emina
Richtig, Georg
Richtig, Erika
Rohrer, Peter Michael
Koch, Lukas
Wolf, Ingrid Hildegard
Koch, Catharina
Rainer, Barbara Margaretha
Koeller, Maximilian
Pichler, Martin
Gerritsmann, Hanno
Kashofer, Karl
Aigelsreiter, Ariane
- DOI
-
10.3390/cancers13123101
- URN
-
urn:nbn:de:bvb:384-opus4-1016045
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:51 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Berger, Marina
- Thueringer, Andrea
- Franz, Doritt
- Dandachi, Nadia
- Talakić, Emina
- Richtig, Georg
- Richtig, Erika
- Rohrer, Peter Michael
- Koch, Lukas
- Wolf, Ingrid Hildegard
- Koch, Catharina
- Rainer, Barbara Margaretha
- Koeller, Maximilian
- Pichler, Martin
- Gerritsmann, Hanno
- Kashofer, Karl
- Aigelsreiter, Ariane
- Universität Augsburg
- MDPI AG
Entstanden
- 2021
Ähnliche Objekte (12)
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Cannabinoids reduce melanoma cell viability and do not interfere with commonly used targeted therapy in metastatic melanoma in vivo and in vitro
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Best of ASCO 2022: bladder cancer
Function and clinical implications of long non-coding RNAs in melanoma
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction of metastatic melanoma
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Inflammation, phagocytosis and cancer: another step in the CD47 act
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Cannabinoids reduce melanoma cell viability and do not interfere with commonly used targeted therapy in metastatic melanoma in vivo and in vitro
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Best of ASCO 2022: bladder cancer
Function and clinical implications of long non-coding RNAs in melanoma
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction of metastatic melanoma
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?
Inflammation, phagocytosis and cancer: another step in the CD47 act
So finden Sie den passenden Coach : der Wegweiser zum Erfolg - Antworten, die das Internet nicht gibt
Prediction of response in melanoma therapy by systemic inflammatory response – one size fits not all
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-magnitude of clinical benefit scale (ESMO-MCBS) version 1.1
Cannabinoids reduce melanoma cell viability and do not interfere with commonly used targeted therapy in metastatic melanoma in vivo and in vitro
High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
Best of ASCO 2022: bladder cancer
Function and clinical implications of long non-coding RNAs in melanoma
Application of circulating cell-free tumor DNA profiles for therapeutic monitoring and outcome prediction of metastatic melanoma
Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition
MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients
Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer — the more specific, the better?